Brassinosteroid Analogue Crystal Forms for Higher Bioactivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for preparing Brassinosteroid (BR) analogues and their crystal forms lack optimization, leading to suboptimal bioactivity and purification efficiency, which affects their agricultural applications.
Innovation Solution
A novel BR analogue with a chemical formula of C27H46O7 and two novel crystal forms, achieved through optimized recrystallization conditions, including specific solvent use and cooling methods, resulting in improved bioactivity and purification.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional recrystallization methods are used for BR analogue preparation, then the preparation process is simple, but the bioactivity and purification efficiency are suboptimal
Solution Approach 1:
The patent optimizes recrystallization parameters including solvent selection (ethyl acetate, n-hexane, ethanol), temperature control (4°C refrigeration), and pH adjustment to obtain crystal forms with significantly improved bioactivity. This resolves the contradiction by systematically modifying process parameters to enhance reliability while maintaining reasonable process complexity
Solution Approach 2:
The patent employs preliminary purification steps including silicagel column chromatography and acid treatment before final recrystallization. These preliminary actions remove impurities that would otherwise interfere with crystal formation, ensuring high bioactivity of the final product without requiring overly complex final step
2Reliability
If multiple crystal forms are obtained through different recrystallization methods, then the bioactivity can be optimized, but the screening process becomes more complex
Solution Approach 1:
The patent uses X-ray powder diffraction (XRPD) and differential scanning calorimetry (DSC) to characterize and differentiate crystal forms instead of relying solely on visual inspection or simple physical property measurements. This substitution of analytical methods makes the screening process more reliable and easier to interpret, resolving the contradiction between optimizing bioactivity through multiple crystal forms and the difficulty of screening them
3Adaptability or versatility
If natural BR analogues are extracted from natural raw materials, then the source is sustainable, but the purification efficiency is limited
Solution Approach 1:
The patent employs silicad chromatography with gradient elution (increasing methanol concentration from 10% to 50%) to achieve localized separation of BR analogues from complex natural extracts. This localized purification approach maintains compatibility with natural sources while dramatically improving purification efficiency by targeting specific compound fractions
Solution Approach 2:
The patent uses acid treatment (HCl or H2SO4) as an intermediary step to modify the chemical properties of extracted compounds, facilitating their separation and crystallization. This intermediary treatment enhances purification efficiency by converting compounds into forms that are easier to separate from natural extract impurities
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The novel BR analogue and crystal forms exhibit significant bioactivity, enhancing plant growth promotion and stress resistance, with improved stability and solubility, demonstrating enhanced agricultural efficacy.
Implementation Method 1
RU2434877C1 discloses a method of producing 7,8-dihydro-analogues of ecdysteroids via catalytic hydrogenation of ecdysteroids in methanol solution containing 1:6-fold excess Na metal in the presence of a Pd/C catalyst
Implementation Method 2
in the presence of a Pd/C catalyst (1:1 to the weight of the substrate)
Implementation Method 3
Compound polymorphism means that the active ingredient of a drug can form two or more molecular assembly modes during crystallization
Implementation Method 4
a preparation process of the crystal form I includes the following steps: 1) extracting a crude extract of a natural BR analogue from rapeseed pollen; 2) dissolving 10 parts to 20 parts of the crude extract of the natural BR analogue in 20 to 30 times a methanol reagent, heating at 50°C to 80°C to promote complete dissolution, filtering an obtained solution I into a test tube while the solution I is hot, sealing the test tube with a parafilm, piercing holes in the parafilm, cooling, and allowing the solution I to stand to conduct volatilization
Data Source
Figure 1
Figure 2
Figure 3~4
AI summary
Disclosed in the present invention are a novel brassinosteroid analogue, a novel crystalline form and a preparation method therefor and an application thereof. The chemical formula of the brassinosteroid analogue is C27H46O7, the chemical name of the brassinosteroid analogue is (20R,22R)-2β,3β,14α-14,20,22,25-hexahydroxy-5β,8α,9α-cholest-6-ketone, and the structural formula is shown as aa. According to the present invention, by improving the recrystallization process of a naturally extracted brassinosteroid analogue, the novel crystalline form having high biological activity can be obtained, and the novel crystalline form can be applied to the field of agriculture to promote plant growth